socalTECH

OCTOBER 12, 2016

Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M The investment came from F-Prime Capital Partners. As part of the funding, F-Prime's Thomas Beck and Ben Auspitz have joined the company's board. in a Series A investment.

Thousand Oaks 100

Thousand Oaks Research Activity Invest 100

socalTECH

FEBRUARY 21, 2013

Xirrus , the wireless hardware provider based in Thousand Oaks, has just raised $10.1M funding, according to a regulatory filing by the company. Details on the funding have not yet been announced by the company. The regulatory filing said that Xirrus will be using the new funds for working capital.

Thousand Oaks 164

Thousand Oaks Conference Networking Capital 164

socalTECH

NOVEMBER 7, 2013

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.

Thousand Oaks 164

Thousand Oaks UCLA Venture Capital Equity 164

socalTECH

SEPTEMBER 8, 2011

Thousand Oaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. According to Seattle-based Theraclone Sciences , Amgen Ventures was one of the investors in a $10.6M, Series B extension round for the company. READ MORE>>.

Thousand Oaks 150

Thousand Oaks Venture Capital Equity Capital 150

socalTECH

APRIL 24, 2012

Amgen Ventures , the venture capital arm of Thousand Oaks-based Amgen , has re-upped on an investment in a biopharmaceuticals developing microRNA-based treatments for cardiovascular and muscle disease. and Broadview Ventures. miRagen is based in Boulder, Colorado.

Thousand Oaks 150

Thousand Oaks Venture Capital Invest Capital 150

socalTECH

MAY 8, 2012

The venture capital arm of Thousand Oaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma , which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M

Thousand Oaks 140

Thousand Oaks Invest Venture Capital Platform 140

socalTECH

APRIL 8, 2014

Thousand Oaks-based drug development company Atara Biotherapeutics announced this morning that it has added Matthew K. Fust as a board member, and hired Mitchall G. Clark as its Chief Regulatory and Quality Assurance Officer. READ MORE>>. atara biotherapeutics renal disease lifescience amgen executive board'

Thousand Oaks 138

Thousand Oaks Invest Capital Funding 138

socalTECH

JANUARY 24, 2011

Thousand Oaks-based biotech giant Amgen said Monday afternoon that it is acquiring Biovex , a Woburn, Massachusetts-based developer of treatments for melanoma and head and neck cancer. BioVex develops OncoVEX, a novel oncolytic vaccine in Phase 3 clinical development. READ MORE>>.

Thousand Oaks 167

Thousand Oaks Sales Invest Capital 167

socalTECH

AUGUST 31, 2011

Amgen Ventures , the venture capital arm of Thousand Oaks-based Amgen , has backed the developer of a biopharmaceutical aimed at treating irritable bowel syndrome, kidney disease, and diabetes.

Thousand Oaks 150

Thousand Oaks Venture Capital Capital Funding 150

socalTECH

FEBRUARY 28, 2012

Thousand Oaks-based Ceres , the developer of seed stock for energy crops, said today that it has closed its IPO, selling a total of 5,750,000 shares of its common stock at $13.00 The firm said its underwriters exercise their full option to purchase an additional 750,000 shares of common stock from the company as part of the IPO.

Thousand Oaks 140

Thousand Oaks Southern California Marketing Capital 140

socalTECH

JULY 6, 2015

Thousand Oaks-based Teledyne Technologies has increased its stake in San Diego-based Ocean Aero , a developer of unmanned, robotic underwater and surface vehicles used for the scientific, defense, and oil and gas market, the company said late Friday. Financial terms of the deal were not disclosed.

Thousand Oaks 100

Thousand Oaks San Diego Invest Marketing 100

socalTECH

JANUARY 25, 2012

Thousand Oaks-based Ceres , the developer of seeds to supply the bioenergy and biofuels feedstock business, has set its initial pricing range for its IPO, according to a filing from the company this morning. per share, raising up to $132.25M for the company. and $23.00

Pricing 145

Pricing Thousand Oaks Design Capital 145

socalTECH

FEBRUARY 22, 2012

Thousand Oaks-based Ceres , the developer of specialized seeds for the biofuels market, has priced its IPO, saying that it will offer up 5,000,000 shares of its common stock at $13.00 Barclays Capital, PIper Jaffray, Raymond James, and Simmons & Company International.

Pricing 150

Pricing Thousand Oaks Startup Design 150

socalTECH

MAY 23, 2011

Thousand Oaks-based Ceres , the developer of seeds aimed at producing renewable, biomass feedstocks for the biofuels industry, has filed for an IPO. According to a filing this morning by the firm, the company is aiming to raise up to $100M in an IPO on the NASDAQ Global Market as CERE. and Barclays Capital.

Thousand Oaks 140

Thousand Oaks .Net Capital Marketing 140

socalTECH

APRIL 12, 2010

Thousand Oaks-based Nexsan , a developer of data storage systems, has delayed its IPO, according to its underwriter, Thomas Weisel Partners. The firm's IPO was being underwritten by Thomas Weisel Partners, Lazard Capital Markets, Needham & Company, and Morgan Keegan & Company. and $12.00 READ MORE>>.

Thousand Oaks 145

Thousand Oaks Marketing Capital Develop 145

socalTECH

JULY 8, 2010

Thousand Oaks-based Ceres , a developer of biofuels crop technology, said Thursday that it has completed a private offering of convertible preferred stock. Financial terms of the funding were not disclosed by the company, however, the firm revealed in a regulatory filing earlier this month that it had raised $20M in a financing.

Thousand Oaks 140

Thousand Oaks Venture Capital Design Activity 140

socalTECH

NOVEMBER 25, 2009

Thousand Oaks-based Xirrus , a developer of Wi-Fi networking hardware, has raised another $20M in funding, according to a regulatory filing from the firm today. Details on the new funding have not yet been announced by the company. Tags: hardware networking wifi capital venture xirrus. READ MORE>>.

Thousand Oaks 145

Thousand Oaks Funding Networking Platform 145

socalTECH

MAY 20, 2010

Thousand Oaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production. Financial details of the partnership were not disclosed.

Thousand Oaks 145

Thousand Oaks Equity Research Product 145

socalTECH

DECEMBER 1, 2009

Thousand Oaks-based Xirrus confirmed Tuesday that it has raised an additional $20M in funding, bringing the firm's total raised to $80M. Xirrus is a developer of Wi-Fi networking hardware, which combines a number of Wi-Fi access points and switching in a single device. The round was led by InterWest Partners. READ MORE>>.

Thousand Oaks 140

Thousand Oaks Funding Venture Capital Networking 140

Xconomy

JULY 22, 2016

The top news in biotech this week centers around one big job opening: the head seat at Biogen, now that George Scangos has announced plans to leave the company. Who takes the gig, and the strategic direction he or she chooses for Biogen will have implications not just for the company and its employees, but the sector overall.

Startup 40

Startup San Diego News Thousand Oaks 40